0300 111 1234


EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

JINARC® (tolvaptan) approved in Europe

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

On 28 May, 2015, the first-ever drug therapy for adults with ADPKD, was approved in Europe.

JINARC® - the brand name of the drug we know more commonly as tolvaptan - was developed by Otsuka Pharmaceutical Co Ltd. The company was granted marketing authorisation for JINARC® (tolvaptan) based on the findings of the pivotal Phase III randomised, double-blind and placebo-controlled TEMPO 3:4 trial – the largest clinical study conducted in ADPKD to date.

Click here for more information about Tolvaptan.

Print Email


Latest Tweets

PKD Charity is a Member of

  • Fundraising Regulator Website
  • Visit The Information Standard website
  • Visit PKD International website
  • Visit Ciliopathy Alliance website
  • Visit the Genetic Alliance UK website
  • Rare Disease UK Website
  • National Voices Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website
  • Visit EURORDIS website